- Home
- BMR vs CUE Comparison
BMR vs CUE Comparison
Compare BMR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- CUE
- Stock Information
- Founded
- BMR 2009
- CUE 2014
- Country
- BMR Israel
- CUE United States
- Employees
- BMR N/A
- CUE 41
- Industry
- BMR Computer Software: Prepackaged Software
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BMR Technology
- CUE Health Care
- Exchange
- BMR Nasdaq
- CUE Nasdaq
- Market Cap
- BMR 59.3M
- CUE 58.9M
- IPO Year
- BMR 2023
- CUE 2018
- Fundamental
- Price
- BMR $2.50
- CUE $0.79
- Analyst Decision
- BMR
- CUE Strong Buy
- Analyst Count
- BMR 0
- CUE 3
- Target Price
- BMR N/A
- CUE $3.00
- AVG Volume (30 Days)
- BMR 86.3K
- CUE 231.4K
- Earning Date
- BMR 05-06-2025
- CUE 05-08-2025
- Dividend Yield
- BMR N/A
- CUE N/A
- EPS Growth
- BMR N/A
- CUE N/A
- EPS
- BMR N/A
- CUE N/A
- Revenue
- BMR $3,064,000.00
- CUE $9,287,000.00
- Revenue This Year
- BMR N/A
- CUE N/A
- Revenue Next Year
- BMR N/A
- CUE $4.77
- P/E Ratio
- BMR N/A
- CUE N/A
- Revenue Growth
- BMR 5.33
- CUE 69.16
- 52 Week Low
- BMR $1.86
- CUE $0.45
- 52 Week High
- BMR $6.71
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- BMR 56.42
- CUE 43.53
- Support Level
- BMR $2.08
- CUE $0.74
- Resistance Level
- BMR $2.30
- CUE $0.86
- Average True Range (ATR)
- BMR 0.21
- CUE 0.09
- MACD
- BMR 0.07
- CUE 0.02
- Stochastic Oscillator
- BMR 90.14
- CUE 66.14
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.